Elafin (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Elafin (PI3; UniProt P19957), expressed in HEK293 cells. A serine protease inhibitor of the WAP-domain family used in neutrophil elastase inhibition assays, inhibitor screens, and antibody validation experiments.
Expression system
HEK293
Cat. #
REC-Elafin

In stock

SKU
REC-Elafin
$498.00

Target Overview

Elafin (UniProt P19957; gene PI3) is a 117-amino-acid secreted serine protease inhibitor belonging to the WAP four-disulfide core (WFDC) domain protein family. It is the founding member of the skin-derived antileukoproteinase (SKALP) group and acts as a potent, specific inhibitor of neutrophil elastase and pancreatic elastase, two serine proteases capable of degrading extracellular matrix components including elastin and collagen. This recombinant Elafin is produced in HEK293 mammalian cells, an expression system that supports the disulfide-bond formation essential for the structural integrity of the WAP domain. Mammalian expression also provides native-like glycosylation and folding, which are important considerations when using recombinant Elafin as a functional standard or inhibitor in biochemical assays. The full-length mature protein span (as annotated in the UniProt P19957 entry) is covered by this construct. In the laboratory, recombinant Elafin is routinely used in several experimental contexts: (1) activity assays measuring inhibition of neutrophil elastase or pancreatic elastase against fluorogenic or chromogenic substrates; (2) inhibitor potency determinations (Ki, IC50) in protease screen panels; (3) as a positive control antigen for validating anti-Elafin antibodies by Western blot, ELISA, or IHC; and (4) as a reference standard in inflammation- and epithelial-barrier research where elastase activity needs to be calibrated. Researchers using this recombinant for antibody validation can pair it directly with the Triple Point Biologics matched anti-Elafin antibody (catalog: RP-Elafin), which has been validated for Western blot applications against human samples, with predicted cross-reactivity to monkey and pig.

Background

Elafin is an endogenous serine protease inhibitor expressed predominantly in epithelial tissues including skin, lung, and the female reproductive tract. It belongs to the whey acidic protein (WAP) four-disulfide core superfamily and exerts its primary inhibitory activity against neutrophil elastase (NE) and pancreatic elastase — two enzymes with well-documented capacity to degrade extracellular matrix proteins and disrupt epithelial barrier integrity. Through this antiprotease activity, Elafin is thought to limit collateral tissue proteolysis during the neutrophilic phase of innate immune responses. Beyond its canonical antiprotease role, published studies have characterised additional biological activities. Elafin has been reported to carry antimicrobial properties against both gram-positive and gram-negative bacteria, potentially through direct membrane disruption independent of protease inhibition. In epithelial barrier research, recombinant Elafin has been used to probe the interplay between elastase activity and tight-junction integrity, with studies in lung and gut epithelial models examining how NE-mediated cleavage of structural proteins is modulated by endogenous inhibitor concentrations. In published inflammation research, Elafin has been studied as a tissue marker of acute and chronic neutrophilic inflammation, including in the context of inflammatory lung diseases such as COPD and cystic fibrosis, as well as in skin conditions such as psoriasis where SKALP/Elafin expression is markedly upregulated in lesional keratinocytes. Elafin has also been investigated in obstetric and reproductive biology; elevated or altered Elafin levels in cervicovaginal fluid have been studied as potential indicators of altered protease balance in preterm birth research. More recent mechanistic characterisation has identified additional molecular targets. Published data (PubMed: 29483648) indicate that Elafin can inhibit the α4β2 nicotinic acetylcholine receptor (CHRNA2/CHRNB2) and produce weak inhibitory effects on the hERG potassium channel (Kv11.1/KCNH2) and TRPV1, expanding the scope of its investigated biology beyond classical antiprotease function and pointing to potential roles at the intersection of protease biology and ion-channel pharmacology. Recombinant Elafin produced in HEK293 is the preferred form for functional inhibition assays, protein–protein interaction studies, and as an antigen standard for quantitative immunoassay development and antibody validation workflows. Its well-defined WAP domain architecture makes it a useful structural reference for researchers studying related WFDC family members.

Applications

  • Neutrophil elastase inhibition activity assay using fluorogenic peptide substrates (e.g., MeOSuc-AAPV-AMC)
  • Pancreatic elastase inhibition assay with chromogenic substrate controls
  • Inhibitor potency determination (Ki, IC50) in serine protease inhibitor screen panels
  • Positive control antigen for anti-Elafin antibody validation by Western blot and ELISA
  • IHC positive control tissue standard preparation using recombinant Elafin-spiked cell lysates
  • Protein–protein interaction studies examining Elafin binding to elastase or WAP-domain binding partners
  • Reference standard for Elafin quantification in sandwich ELISA development (cervicovaginal fluid, bronchoalveolar lavage)
  • Substrate competition assay to determine selectivity of experimental elastase inhibitor compounds against an endogenous inhibitor benchmark

References

  1. Rathbun AM et al. Characterization of the plasma proteomic profile of dual trajectories in cognitive status and physical performance. Geroscience. 2026. doi:10.1007/s11357-026-02356-y. PMID: 42301613.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight should I expect for recombinant Elafin on SDS-PAGE and Western blot?

The mature Elafin sequence (UniProt P19957) encodes a 117-amino-acid protein with a predicted molecular weight of approximately 9.9 kDa. However, HEK293-expressed recombinant Elafin typically migrates at 12–15 kDa under reducing SDS-PAGE conditions due to native-like N-linked glycosylation. Under non-reducing conditions, the four conserved disulfide bonds of the WAP domain can cause aberrant migration; always run reducing gels unless your assay specifically requires non-reduced samples. Purity is confirmed at >95% by SDS-PAGE.

Is this recombinant Elafin the mature secreted form or does it include the transglutaminase-binding trappin domain?

This construct covers the full-length mature protein as annotated in UniProt P19957, which includes both the N-terminal cementoin/trappin domain (responsible for transglutaminase-mediated cross-linking to ECM) and the C-terminal WAP four-disulfide core domain that carries the elastase-inhibitory activity. The 22-amino-acid signal peptide is absent, as expected for the secreted form. Researchers studying tissue-bound Elafin deposition versus free soluble inhibitor should take the presence of the trappin domain into account when designing binding or cross-linking assays.

What substrates and assay conditions should I use to measure recombinant Elafin inhibitory activity against neutrophil elastase?

The standard functional assay pairs recombinant Elafin against human neutrophil elastase (HNE) using the chromogenic substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (MeOSuc-AAPV-pNA) at 1–2 mM in 100 mM HEPES pH 7.5, 0.05% Tween-20, 37 °C. Pre-incubate Elafin with HNE for 15–30 minutes before substrate addition to allow tight-binding complex formation. Residual elastase activity is read at A405 nm. This assay is also suitable for pancreatic elastase. Elafin should not be used to inhibit other serine proteases such as thrombin or trypsin, where it shows no meaningful inhibition.

What is the expected IC50 of recombinant Elafin against human neutrophil elastase and what starting concentration do you recommend?

Elafin is a tight-binding, near-stoichiometric inhibitor of human neutrophil elastase (Ki reported in the low nanomolar range, ~0.2–1 nM). Because tight-binding kinetics make classical IC50 determination enzyme-concentration-dependent, apparent IC50 values vary with HNE concentration used. For a practical starting point, use a 1:1 to 5:1 molar ratio of Elafin to HNE, beginning at 50–200 nM Elafin with 50 nM HNE. Confirm activity in your specific buffer — the product is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and is compatible with standard elastase assay buffers after dilution.

Does the storage buffer for recombinant Elafin interfere with elastase activity assays?

The supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is generally compatible with elastase inhibition assays when Elafin is diluted at least 1:10 into the assay buffer. Glycerol at >1% final concentration can slightly reduce substrate cleavage rates; we recommend diluting to ≤1% glycerol in the assay. Tris and NaCl at these carry-over concentrations do not meaningfully affect HNE activity. If your assay requires phosphate-buffered conditions, dilute the protein into assay buffer immediately before use — Elafin is stable for up to 24 hours at 4 °C post-dilution.

Can I use recombinant Elafin as a positive control for Western blot with the TPB anti-Elafin rabbit polyclonal antibody?

Yes. Recombinant Elafin (REC-Elafin) is the recommended positive control for the matched rabbit polyclonal antibody (RP-Elafin; see /anti-elafin-rabbit-polyclonal-antibody). Both reagents are produced and validated in the same laboratory, ensuring epitope compatibility. Load 10–50 ng of recombinant Elafin per lane on a 15–18% SDS-PAGE gel (reducing conditions); the antibody detects the glycosylated band at 12–15 kDa. This pairing is also suitable for antibody titration experiments and as a molecular weight reference when probing tissue lysates where endogenous Elafin may appear at the same apparent MW.

How much recombinant Elafin should I load as a Western blot positive control, and what band will I see?

For a clear, non-saturating signal with the RP-Elafin antibody, load 20–50 ng per lane. At 20 ng you should detect a single band at ~12–15 kDa (reducing, denaturing conditions) corresponding to the glycosylated mature protein. If you observe a faint secondary band near 10 kDa in some preparations, this reflects a minor deglycosylated species and is normal. Use a 15% or 4–20% gradient gel to resolve this size range adequately. Endotoxin is <0.1 EU/µg by LAL, so the recombinant is also suitable as a loading control in cell-stimulation experiments where LPS contamination must be excluded.

What is the recommended storage and handling protocol for recombinant Elafin to maintain activity long-term?

Store recombinant Elafin at -20 °C in the single-use aliquots as supplied. Avoid repeated freeze-thaw cycles — each cycle can reduce WAP-domain disulfide integrity and measurably decrease elastase-inhibitory activity. Upon first thaw, briefly centrifuge (1,000 × g, 30 s) to collect any condensate, then dilute to working concentration in assay buffer immediately before use. For short-term use within 48 hours, the protein is stable at 4 °C. Do not store at room temperature. Carrier protein (0.1% BSA) may be added to diluted aliquots if protein loss to tube surfaces is a concern at concentrations below 10 µg/mL.

Validation imagery coming soon

Western blot validation figures for REC-Elafin will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →